Journal article

Effect of ten-valent pneumococcal conjugate vaccine introduction on pneumonia hospital admissions in Fiji: a time-series analysis

Rita Reyburn, Evelyn Tuivaga, Cattram D Nguyen, Felisita T Ratu, Devina Nand, Joe Kado, Lisi Tikoduadua, Kylie Jenkins, Margaret de Campo, Mike Kama, Rachel Devi, Eric Rafai, Daniel M Weinberger, E Kim Mulholland, Fiona M Russell

The Lancet Global Health | ELSEVIER SCI LTD | Published : 2021

Abstract

BACKGROUND: In October, 2012, Fiji introduced routine infant immunisation with a ten-valent pneumococcal conjugate vaccine (PCV10) using three primary doses and no booster dose (3 + 0 schedule). Data are scarce for the effect of PCV in the Asia and Pacific region. We aimed to evaluate the effect of PCV10 on pneumonia hospital admissions in children younger than 5 years and adults aged 55 years and older in Fiji, 5 years after vaccine introduction. METHODS: We did a time-series analysis assessing changes in pneumonia hospital admissions at three public tertiary hospitals in Fiji. Four pneumonia outcomes were evaluated: all-cause pneumonia, severe or very severe pneumonia, hypoxic pneumonia, a..

View full abstract

Grants

Awarded by Bill & Melinda Gates Foundation


Awarded by National Institute of Allergy and Infectious Diseases


Funding Acknowledgements

We acknowledge the major contribution from the Ministry of Health and Medical Services in particular the staff of the Colonial War Memorial Hospital paediatric department, the paediatric records clerks, the new vaccine evaluation staff, Murdoch Children's Research Institute staff, and the health informatics consultant for Fiji Health Sector Support Program (FHSSP). This study was supported by the Department of Foreign Affairs and Trade of the Australian Government FHSSP. FHSSP is implemented by Abt JTA on behalf of the Australian Government. FMR is supported by grants from the Australian National Health and Medical Research Council. During the conduct of this study DMW was supported by grants OPP117626 from the Bill & Melinda Gates Foundation and R01AI123208 from the National Institute of Allergy and Infectious Diseases. We thank Kayoko Shioda and Josh Warren for discussion of these analyses.